A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05907980
• Other study ID #: RSE101CT
• Status: Recruiting
• Phase: Phase 1
• Start date: May 24, 2023
• Est. completion date: December 31, 2026

Study information

• Verified date: September 2023
• Source: Chugai Pharmaceutical
• Contact: Clinical trials information
• Phone: only use Email
• Email: clinical-trials[@]chugai-pharm.co.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 219
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years at time of signing informed consent form (ICF)

• Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

• Adequate hematologic and end-organ function

• Life expectancy >= 12 weeks

• Patients with histologic documentation of locally advanced, or metastatic solid tumor

• [Dose-escalation Parts and Biopsy Parts]Refractory or resistant to standard therapies or standard therapies are not available

• [Dose-escalation Parts and Expansion Part] Patients with confirmed availability of fresh tumor or representative tumor specimens

• [Biopsy Parts] Patients with accessible lesion(s)

Exclusion Criteria:

• Clinically significant cardiovascular or liver disease

• Treatment with investigational therapy and anti-cancer therapy within 28 days prior to initiation of study drug

• Any history of an immune-mediated Grade 4 adverse event attributed to prior cancer immunotherapy (other than asymptomatic elevation of serum amylase or lipase).

• All imAEs from prior cancer immunotherapy (other than endocrinopathy managed with replacement therapy, stable vitiligo or stable alopecia) that have not resolved completely to baseline.

• Adverse events from prior anti-cancer therapy that have not resolved to Grade = 1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy

• Primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases

• Uncontrolled tumor-related pain

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

• Active or history of clinically significant autoimmune disease

• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

[Expansion Part]

• Prior treatment with investigational product which has MoA of Treg depletion

• Malignancies other than disease under study within 5 years prior to Cycle 1 Day 1

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• ROSE12
ROSE12 as a IV infusion
• Atezolizumab
Atezolizumab as a IV infusion

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital	Chuo-ku	Tokyo
Japan	National Cancer Center Hospital East	Kashiwa-shi	Chiba
United States	NEXT Oncology	Fairfax	Virginia
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Chugai Pharmaceutical

Countries where clinical trial is conducted

United States,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum tolerated dose (MTD) and the recommended dose (RD) of ROSE12 when administered as a single agent and in combination with atezolizumab (Part A and C)	Incidence and nature of dose-limiting toxicities (DLTs)	From Cycle 1 Day 1 until Cycle 1 Day 21 (Cycle 1 is 21 days)
Primary	Safety (All Parts) and tolerability (Part A, B, C and D) of ROSE12 when administered as a single agent and in combination with atezolizumab (Adverse Events)	Incidence, nature, and severity of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	From screening until study completion, treatment discontinuation or post-treatment follow up, assessed up to the end of the study (approximate 43 months)
Primary	The maximum serum concentration (Cmax) of ROSE12 for PK profile when administered as a single agent and in combination with atezolizumab (All Parts)	The maximum serum concentration (Cmax) of ROSE12	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Primary	The minimum serum concentration (Cmin) of ROSE12 for PK profile when administered as a single agent and in combination with atezolizumab (All Parts)	The minimum serum concentration (Cmin) of ROSE12	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Primary	The area under the concentration time-curve (AUC) of ROSE12 for PK profile when administered as a single agent and in combination with atezolizumab (All Parts)	The area under the concentration time-curve (AUC) of ROSE12	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Primary	Preliminary anti-tumor activity of ROSE12 when administered in combination with atezolizumab (Part E)	Objective response rate (ORR), defined as the proportion of patients with an objective response (complete response [CR] or partial response [PR]) on two consecutive occasions = 4 weeks apart, as determined by the investigator according to the Response Evaluation Criteria in Solid Tumors version 1.1	From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (Part A, B, C and D)	ORR, defined as the proportion of patients with an objective response on two consecutive occasions = 4 weeks apart, as determined by the investigator according to RECIST v1.1.	From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts)	Disease control rate (DCR), defined as the proportion of patients who had an objective response or stable disease (SD) which is confirmed no less than 6 weeks after the start of treatment as the minimum duration, as determined by the investigator with use of RECIST v1.1.	From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts)	Duration of objective response (DoR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.	From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts)	Progression-free survival (PFS), defined as the time from administration of first study treatment to the first occurrence of disease progression or death from any cause, as determined by the investigator according to RECIST v1.1.	From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	The maximum serum concentration (Cmax) of atezolizumab for PK profile when administered in combination with ROSE12 (Part C, D and E)	The maximum serum concentration (Cmax) of atezolizumab	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	The minimum serum concentration (Cmin) of atezolizumab for PK profile when administered in combination with ROSE12 (Part C, D and E)	The minimum serum concentration (Cmin) of atezolizumab	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	The area under the concentration-time curve (AUC) of atezolizumab for PK profile when administered in combination with ROSE12 (Part C, D and E)	The area under the concentration-time curve (AUC) of atezolizumab	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	The immunogenicity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts)	Prevalence and incidence of anti-drug antibodies (ADAs) to ROSE12 and potential correlation with PK parameters and safety	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)
Secondary	The immunogenicity of atezolizumab when administered in combination with ROSE12 (Part C, D and E)	Prevalence and incidence of ADAs to atezolizumab and potential correlation with PK parameters and safety	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)